LAUSANNE, Switzerland, December 10 /PRNewswire/ -- Diagnoplex, a developer of molecular cancer diagnostics today announced the closing of a Series A financing raising CHF10 million ($8.3 million). The A-round was led by Novartis Venture Fund and NeoMed, with Initiative Capital Romandie acting as co-investor. The Novartis Venture Fund was also a seed investor in the company. BCCC Avocats acted as counsel to the investors and BMP AssociÃ©s acted as counsel to the company.
In connection with the financing, Anja KÃ¶nig, Ph.D., a Managing Director of Novartis Venture Fund, and Thomas Goebel, Ph.D., a Principal at NeoMed, will join Diagnoplex' board of directors, while Claude Suard, Partner at DEFI Gestion, will join the board as an observer.
Diagnoplex technology platform
Leveraging its unique and proprietary molecular platform capabilities,
Diagnoplex develops blood-based cancer diagnostics. Diagnoplex'
single-channel quantitative multiplex reverse transcriptase-polymerase chain
reaction (scqmRT-PCR) yields the quantification of copy number obtained with
real-time PCR, and allows quantifying up to 60 genes simultaneously. The
scqmRT-PCR platform offers several important competitive advantages. It pairs
the high accuracy and reliability of PCR with the possibility to read out
multi-gene signatures of different cancers. As opposed to microarray
platforms, it is easily scalable and can be run in most standard testing
laboratories. Stavros Therianos, PhD, founder and chief executive officer of
Diagnoplex, developed the platform during his tenure at
Diagnoplex lead product - Colox
Diagnoplex will use the proceeds from the financing to support the
further clinical development of its lead product Colox, a non-invasive test
for the early detection of colon cancer, which will be made available as a
ready-to-use clinical laboratory kit. Early result
Copyright©2008 PR Newswire.
All rights reserved